AstraZeneca (NASDAQ: AZN) and Bristol Myers Squibb (NYSE: BMY) have reportedly held preliminary discussions regarding a potential $400 billion cash-and-stock merger, according to the Financial Times. If completed, the transaction would create the world's fourth-largest pharmaceutical company by market capitalization. The companies are said to be in the early stages of discussions, and the proposed structure remains uncertain. Sector: Pharmaceuticals Key Highlights 🤝 AstraZeneca and Bristol Myers held preliminary merger discussions 💰 Potential deal valued at approximately $400 billion 📊 Proposed structure includes a cash-and-stock combination 🌍 Could create the world's fourth-largest drugmaker by market value ⚠️ Talks remain preliminary and may not result in a transaction Why It Matters A merger of this scale would reshape the global pharmaceutical industry by combining two leading drugmakers with broad oncology, cardiovascular, and immunology portfolios. However, discussions remain exploratory, and there is no certainty that a deal will be reached. Read More: https://www.thinksabio.com/reports/isr/AZN